IBD 50: Auto, Other IBD 50 Stocks Forming Bases
at Investor's Business Daily - Thu Apr 17, 5:53PM CDT
Thanks to a longer market contraction, about a dozen IBD 50 stocks are forming bases, making those stocks worth a closer look. The major indexes have sunk longer and deeper than previous declines since the start of 2013. That's given some leading...
Eli Lilly/ Boehringer Drug Under FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 4:25PM CDT
Eli Lilly/ Boehringer new drug application (NDA) for their empagliflozin/Tradjenta (linagliptin) combination has been accepted for review by the FDA for type II diabetes.
Encouraging Results from Lexicon Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 4:20PM CDT
Lexicon announced encouraging results from a phase II study on LX4211.
MannKind's Overly-Optimisitic Investors
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 4:47PM CDT
Last week, MannKind announced that the Food and Drug Administration was delaying a decision about whether to approve its inhaled insulin Afezza by three months. Investors seemed surprised, with shares falling 8% on Monday, although it made all...
Novo Nordisk A/S - Share repurchase programme
GlobeNewswire - Mon Apr 14, 5:07AM CDT
On 30 January 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2014.
Global and Chinese Insulin Industry Report 2014
M2 - Thu Apr 10, 9:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hh8c2z/global_and) has announced the addition of the "Global and Chinese Insulin Industry Report 2014" report to their offering. The Global and Chinese Insulin Industry Report 2014 is a professional and in-depth study on the current state of the global insulin industry with a focus on the Chinese situation. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. Insulin market analysis is provided for both the international and Chinese domestic situations including development trends, competitive landscape analysis, key regions development status and a comparison analysis between the international and Chinese markets. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Insulin industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on seven industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. Insulin industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - Insulin Industry Overview - Insulin International and China Market Analysis - Insulin Development Environmental Analysis - Insulin Development Policy and Plan - Insulin Manufacturing Process and Cost Structure - 2009-2014 Insulin Productions Supply Sales Demand Market Status and Forecast - Insulin Key Manufacturers Analysis - Up and Down Stream Industry Analysis - Insulin Marketing Channels Analysis - Insulin Industry Development Trend - Insulin Industry Development Proposals - Insulin New Project Investment Feasibility Analysis - Global and China Insulin Industry Research Conclusions Companies Mentioned - Bioton - Dongbao - Eli Lilly - Gan & Lee - Novo Nordisk - Sanofi - United Laboratories (TUL) For more information visit http://www.researchandmarkets.com/research/hh8c2z/global_and
Global Obesity Therapeutics Market 2013-2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
M2 - Thu Apr 10, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2442zl/obesity) has announced the addition of the "Global Obesity Therapeutics Market 2013-2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity" report to their offering. The current market, which is dominated by off-patent orlistat products, is expected to grow at a modest Compound Annual Growth Rate (CAGR) of 20.7% from approximately $750m in 2012 to approximately $2.6 billion in 2019 Obesity is often described as a global endemic, with incidence dramatically increasing over the past decades, particularly in developed countries. Being overweight or obese is a major risk factor in the development of many chronic diseases, including cardiovascular diseases, cancer, and diabetes, of which treatment incurs extensive economic and healthcare costs. Numerous anti-obesity drugs have been approved in the past decade, including Knoll Pharmaceutical's Meridia (sibutramine) and Acomplia (rimonabant), only for them to be removed from the market due to evidence of suicidal thoughts, depression and cardiovascular problems with their long-term use. As such, healthcare professionals have a negative perception of such drugs and do not widely prescribe them, a major barrier to the growth of the anti-obesity therapeutics market. Only orlistat is currently deemed safe for the long-term treatment of obesity; being proven to produce a placebo-adjusted weight-loss average of a limited 3kg. Two anti-obesity drugs were approved in June and July 2012, and the authors believe that only one, Vivus' Qsymia, has a strong enough safety and efficacy (average placebo-adjusted weight loss of 5kg at the medium dose) profile to make a significant impact on the market, providing it is proven safe in long-term-use studies. If proven safe, the authors expect the sales of Qsymia and other drugs expected to be approved over the forecast period to increase the market size to $2.7 billion. Although moderate, this is significantly below the market potential given the size of the prevalence population. Optimally safe and effective anti-obesity drugs which overcome healthcare professionals' negative opinions will have to be developed if the size of the market is ever to reflect the prevalence of obesity. Key Topics Covered: - Tables & Figures - Introduction - Marketed Products - Pipeline - Market Forecasts - Licensing and Co-Development Deals - Appendix Products Mentioned - Cametor, Norgine BV - Contrave, Orexigen Therapeutics - Victoza, Novo Nordisk - Tesofensine (NeuroSearch) For more information visit http://www.researchandmarkets.com/research/2442zl/obesity
Global Type 2 Diabetes Therapeutics Market 2013-2019
M2 - Thu Apr 10, 2:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tsb7tm/type_2_diabetes) has announced the addition of the "Global Type 2 Diabetes Therapeutics Market 2013-2019 " report to their offering. The value of the global market has the potential to grow to reach $38.8 billion by 2019. There is currently a large number of blood glucose-lowering drugs in the crowded type 2 diabetes market indicated for the treatment of chronically high blood glucose. The market is led by Lantus, which achieved global sales amounting to $6.4 billion in 2012. Over the forecast period from 2012 to 2019, the safer, more efficacious newer classes of drug (GLP-1 agonists, DPP-4 Inhibitors and SGLT-2 inhibitors) are expected to capture substantial market shares, largely replacing older classes such as sulfonylureas and thiazolidinediones. Additionally, a variety of novel drugs belonging to these newer classes are due to enter the market, and are expected to offer a moderate improvement in terms of efficacy and safety. The price of these new therapies is expected to be high, but this is unlikely to hinder their uptake. Scope - A brief introduction to type 2 diabetes, including the symptoms, pathogenesis, risk factors and diagnosis - In-depth analysis of major glucose-lowering drugs for type 2 diabetes, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. Includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters. - Comprehensive review of the pipeline for type 2 diabetes therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets. - Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action - Multi-scenario forecast data for the market up to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain - Discussion of the drivers and barriers for market growth Key Topics Covered: - Tables & Figures - Introduction - Key Marketed Products - Pipeline for Type 2 Diabetes - Market Forecast to 2019 - Deals and Strategic Consolidations - Appendix Companies Mentioned - Astrazeneca - Boehringer Ingelheim - Bristol-Myers Squibb - Byetta And Bydureon - Daiichi Sankyo - Glaxosmithkline - Janssen - Merck & Co - Mitsubishi Tanabe - Novartis - Novo Nordisk - Sanofi - Takeda - Takeda Pharmaceuticals Limited For more information visit http://www.researchandmarkets.com/research/ts...2_diabetes
Global Insulin Delivery Devices Market to 2019
M2 - Wed Apr 09, 8:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h59w23/insulin_delivery) has announced the addition of the "Insulin Delivery Devices Market to 2019 - Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers" report to their offering. The global insulin delivery devices market was valued at $8.8 billion in 2012 and is forecast to reach $13.8 billion by 2019, at a CAGR of 7%. Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers Growth in developed economies such as the US and Europe is attributed to an increasing preference for insulin pumps and the uptake of technical advances such as artificial pancreas devices. Supply-side initiatives aim to develop artificial pancreas devices that closely mimic the pancreas by using rapid-acting insulin and multiple hormone-secreting devices for the effective control of blood glucose. The growth in developing economies is attributed to the high prevalence of diabetes and low penetration of insulin delivery devices in these countries. Collaborations among companies and research foundations such as the Juvenile Diabetes Research Foundation (JDRF) help foster innovation in the diabetes care devices market. Many of these collaborations aim to develop artificial pancreas devices that can effectively replace the pancreas, ensuring the effective management of diabetes. Emerging economies such as India and China are expected to grow at the fastest pace during the 2012-2019 forecast period. While developed economies will witness increasing uptake of technically advanced devices, emerging economies will continue to see increasing uptake for conventional insulin delivery devices such as insulin pens, due to their lower cost." Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Diabetes - Disease Overview 4 Diabetes - Epidemiology 5 Global Insulin Delivery Devices Market: Device Overview 6 Global Insulin Delivery Devices Market: Market Characterization 7 Global Insulin Delivery Devices Market: Segment Analysis and Forecasts 8 Global Insulin Delivery Devices Market: Country Analysis and Forecasts 9 Global Insulin Delivery Devices Market: Reimbursement System 10 Global Insulin Delivery Devices Market: Competitive Landscape Companies Mentioned - Abbott Laboratories - Animas - Antares Pharma - Asante Solutions - Becton, Dickinson and Company - Bioject Medical Technologies - Eli Lilly - F. Hoffmann-La Roche - Injex - Equidyne Systems - Insulet - Medtronic - Novo Nordisk (Subsidiary of Novo A/S) - Owen Mumford - Sanofi - Shanghai Fosun Pharmaceutical - Tandem Diabetes Care - Tonghua Dongbao Pharmaceutical - Ypsomed For more information visit http://www.researchandmarkets.com/research/h5...n_delivery
Alexion, Biogen Among Leading Big-Cap Biotechs
at Investor's Business Daily - Wed Apr 09, 7:02AM CDT
Growth stocks are taking a hit now that the market is in a correction. Biotechs saw a recent sell-off over concerns that the sector was overheating, but biotechs and medical stocks are among leading big-cap stocks. IBD's Big Cap Screen of the Day...
MannKind Slips on Afrezza Approval Delay - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:52AM CDT
The PDUFA date for MannKind's Afrezza was pushed back by the FDA by three months to Jul 15.
Upcoming Events, Shares, Stock Price Updates, Notes Exchange Offer, Clinical Study Results and New Product Launch - Analyst Notes on Salix, Endo, ISIS, IDEXX, and Novo
PR Newswire - Tue Apr 08, 1:17AM CDT
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Endo International PLC (NASDAQ: ENDP), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), IDEXX Laboratories, Inc. (NASDAQ: IDXX), and Novo Nordisk A/S (NYSE: NVO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Does Biogen Idec Inc Have a New Blockbuster Hemophilia Therapy?
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 07, 1:30PM CDT
The FDA recently approved Biogen Idec 's Alprolix for the treatment of hemophilia B. The longer-lasting therapy's convenient dosing requirements may help it quickly dig into Pfizer 's BeneFIX market share. The Alprolix marketing team better...
The US Diabetic Devices Industry Outlook to 2018 - Growth to be Led by Next Generation Technology
M2 - Mon Apr 07, 11:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3z9ktc/the_us_diabetic) has announced the addition of the "The US Diabetic Devices Industry Outlook to 2018 - Growth to be Led by Next Generation Technology" report to their offering. The report titled The US Diabetic Devices Industry Outlook to 2018- Growth to be Led by Next Generation Technology presents a comprehensive analysis of the industry covering aspects including market size of SMBG devices, CGM systems and Insulin Delivery Devices market by revenue and market segmentation by product categories in SMBG devices and Insulin Delivery Devices market. The report also entails a detailed description on the recent trends and developments in the diabetic care devices market and competitive scenario of major players in the industry along with market share of major companies in SMBG devices and Insulin Delivery devices market. Key Topics Covered: 1. The US Diabetes Care Devices Market Introduction 1.1. What is Diabetes and it's Types? 2. The US Diabetes Care Devices Market Size, 2007-2013 3. The US Diabetes Care Devices Market Segmentation, 2007-2013 3.1. By Blood Sugar Monitoring Devices, CGM Devices and Insulin Delivery Devices, 2010-2013 3.2. The US Self Blood Glucose Monitoring Devices Market Introduction 3.3. The US CGM Systems Market Introduction 3.4. The US Insulin Delivery Devices Market Size and Introduction, 2007-2013 3.5. Cause & Effect Relationship Analysis in the US Diabetic Care Devices Industry 4. Artificial Pancreas - The Ultimate Goal 5. Trends and Developments in the US Diabetic Care Devices Market 6. Prevalence of Diabetes across the US States 7. Patents Scenario in the US Diabetic Therapeutic Market 8. Strategic Partnerships and Acquisitions in the US Diabetic Market 9. The US Diabetic Care Devices Market SWOT Analysis 10. Company Profiles of Major Players in the US Diabetic Care Devices Market 11. The US Diabetic Care Devices Market Future Outlook and Projections, 2014-2018 12. The US Macro Economic Indicators: Current and Projections 12.1. Ageing Population in the US, 2007-2018 12.2. Consumer Healthcare Expenditure, 2007-2018 12.3. Diabetic Population in the US, 2007-2018 13. Appendix Companies Mentioned - Abbot laboratories - Dexcom inc - Insulet Corporation - LifeScan Inc - Medtronics - Novo Nordisk - Roche Diagnostics For more information visit http://www.researchandmarkets.com/research/3z...s_diabetic
Salix Among Stocks Getting Support At 10-Week Line
at Investor's Business Daily - Thu Apr 03, 5:13PM CDT
A number of leading stocks in Your Weekly Review are in a secondary buy range amid the market's renewed uptrend. Stocks in the highly rated Medical-Ethical Drugs industry again led this week's list, which expanded to 109 members after shrinking to...
Biosimulation Trends - Global Market Overview 2014-2017
M2 - Thu Apr 03, 10:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bclc3f/biosimulation) has announced the addition of the "Biosimulation Trends" report to their offering. Biosimulation is the mathematical simulation of complex, large biological processes on a computer. Biosimulation is being adopted at a faster pace, to extract and interpret vital data from experiments during drug discovery and development. The report analyzes and presents an overview of Biosimulation market worldwide. The report provides global market estimates and projections for Biosimulation in US dollars for the years 2012 through 2017. Supported with 1 market data table, the report highlights the ever increasing permanence of Biosimulation. The report also provides a review of Biosimulation Models, and Biosimulation software. Key Topics Covered: 1. BIOSIMULATION - A MARKET OVERVIEW - A Prelude - Biosimulation - Revolutionizing Drug Discovery - Biosimulation - Models - Biosimulation Software 2. RECENT INDUSTRY ACTIVITY - Accelrys Introduces Discovery Studio 3.5 - Rhenovia Pharma Introduces Drug Development Programs for Orphan, Neglected and Rare Neurodegenerative Diseases - Rhenovia Pharma Sets Up International Subsidiary in the US - Rhenovia Pharma Inks an Agreement with Portmann - Entelos and RegeneMed Introduce iToxFX Service 3. MARKET PARTICIPANTS - Accelrys, Inc. - Advanced Chemistry Development, Inc. - Anoixis Corporation - Aptiv Solutions - Chemical Computing Group, Inc. - Cognigen Corporation - Compugen Ltd. - Entelos, Inc. - Genedata AG - GNS Healthcare - Immunetrics, Inc. - INOSIM Software GmbH - Insilico Biotechnology AG - Kinetigen, Inc. - LeadInvent - Leadscope, Inc. - Molecular Knowledge Systems, Inc. - Nimbus Discovery LLC - Novo Nordisk A/S - Open Eye Scientific Software, Inc. - Optimata Ltd. - PhinC Development - Physiomics PLC - Rhenovia Pharma SAS - Rosa & Company LLC - Schrodinger LLC - Simcyp Ltd. - Tessella Ltd. - TheraSim - VirtuCel, Inc. 4. APPENDIX For more information visit http://www.researchandmarkets.com/research/bc...simulation
Will Biogen Idec Inc. Rule Biotech in 2014?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 03, 8:30AM CDT
The biotech sector's endured an up-and-down 2014 after the immense gains captured in 2013's market rise, but don't tell that to fast-rising Biogen Idec . Biogen's stock has roared higher by more than 10% in 2014 after experiencing a tremendous...
Involvement of International Pharmaceutical Companies in ChinaBio(R) Partnering Forum 2014 Echoes Compelling China Market Demand
Business Wire - Thu Apr 03, 8:01AM CDT
The 2014 edition of ChinaBio(R) Partnering Forum, China's only life science partnering event, is just weeks away, to be held May 7-8 at the Kempinski Hotel in Suzhou.
Victoza (Obesity) - Forecast and Market Analysis to 2022
M2 - Thu Apr 03, 5:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dxdmrx/victoza_obesity) has announced the addition of the "Victoza (Obesity) - Forecast and Market Analysis to 2022" report to their offering. After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients. Victoza was approved by the FDA in 2010 as a once-daily injection to treat type 2 diabetes in adults. It is also available in the 5EU, as well as in Canada, for the same indication and use. It is not expected to be a presence in the Japanese market, as Novo Nordisk has not indicated any plans for expansion there, or in the Brazilian market, as diabetic therapies in this market are OTC. Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Victoza (liraglutide) 9 Appendix For more information visit http://www.researchandmarkets.com/research/dx...za_obesity